Anergis Picks up $19.6M in First VC Round Since Founding
By Nuala Moran
Tuesday, March 29, 2011
LONDON Anergis SA raised CHF18 million (US$19.6 million) in a Series A round to fund the development of allergy vaccines based on synthetic versions of natural allergens, which it said will be able to induce tolerance more quickly than is the case with de-sensitizing through the long-term administration of natural allergens.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.